The IGF system after insertion of a transjugular in trahepatic porto-systemic shunt in patients with liver cirrhosis

European Journal of Endocrinology

Volumn 160, Issue 6, 2009, Pages 957-963

  Holland Fischer, Peter ^a   Vilstrup, Hendrik ^a   Frystyk, Jan ^a   Nielsen, Dennis Tøonner ^a   Flyvbjerg, Allan ^a   Grøonbæk, Henning ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSE; GLUCAGON; GLUCOSE; INSULIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTIVE SURGERY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT RESPONSE; BLOOD; CALORIC INTAKE; LIVER; METABOLISM; MIDDLE AGED; PROTEIN INTAKE;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; DIETARY PROTEINS; ENERGY INTAKE; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SOMATOMEDINS;

EID: 66149090682     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0971     Document Type: Article

References (50)

1. Andersen H, Borre M, Jakobsen J, Andersen PH & Vilstrup H. Decreased muscle strength in patients with alcoholic liver cirrhosis in relation to nutritional status, alcohol abstinence, liver function, and neuropathy. Hepatology 1998 27 1200-1206.
2. Merli M, Riggio O & Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi) Hepatology 1996 23 1041-1046.
3. Selberg O, Bottcher J, Tusch G, Pichlmayr R, Henkel E & Muller MJ. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997 25 652-657.
4. Allard JP, Chau J, Sandokji K, Blendis LM & Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. American Journal of Gastroenterology 2001 962442-2447.
5. Plauth M, Schutz T, Buckendahl DP, Kreymann G, Pirlich M, Grungreiff S, Romaniuk P, Ertl S,Weiss ML & Lochs H.Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. Journal of Hepatology 2004 40 228-233.
6. Chen JW, Nielsen MF, Caumo A, Vilstrup H, Christiansen JS & Frystyk J. Changes in bioactive IGF1 and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. European Journal of Endocrinology 2006 155 285-292.
7. Hernandez A, Zorrilla E & Gershberg H. Decreased insulin production, elevated growth hormone levels, and glucose intolerance in liver disease. Journal of Laboratory and Clinical Medicine 1969 73 25-33.
8. Samaan NA, Stone DB & Eckhardt RD. Serum glucose, insulin, and growth hormone in chronic hepatic cirrhosis. Archives of Internal Medicine 1969 124 149-152.
9. Wu YL, Ye J, Zhang S, Zhong J & Xi RP. Clinical significance of serum IGF1, IGF2 and IGFBP-3 in liver cirrhosis. World Journal of Gastroenterology 2004 10 2740-2743.
10. Fryburg DA, Jahn LA, Hill SA, Oliveras DM & Barrett EJ. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. Journal of Clinical Investigation 1995 96 1722-1729.
11. Guler HP, Zapf J & Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. New England Journal of Medicine 1987 317 137-140.
12. Russell-Jones DL, Umpleby AM, Hennessy TR, Bowes SB, Shojaee-Moradie F, Hopkins KD, Jackson NC, Kelly JM, Jones RH & Sonksen PH. Use of a leucine clamp to demonstrate that IGF1 actively stimulates protein synthesis in normal humans. American Journal of Physiology 1994 267 E591-E598.
13. Conover CA, Lee PD, Kanaley JA, Clarkson JT & Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. Journal of Clinical Endocrinology and Metabolism 1992 74 1355-1360.
14. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormone and IGF Research 2004 14 337-375.
15. Ooi GT, Tseng LY & Rechler MM. Post-transcriptional regulation of insulin-like growth factor binding protein-2 mRNA in diabetic rat liver. Biochemical and Biophysical Research Communications 1992 189 1031-1037.
16. Paolisso G, Tagliamonte MR, Rizzo MR, Carella C, Gambardella A, BarbieriM& VarricchioM. Low plasma insulin-like growth factor-1 concentrations predict worsening of insulin-mediated glucose uptake in older people. Journal of the American Geriatrics Society 1999 47 1312-1318.
17. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB & Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002 359 1740-1745.
18. Scharf JG, Schmitz F, Frystyk J, Skjaerbaek C, Moesus H, Blum WF, Ramadori G & Hartmann H. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. Journal of Hepatology 1996 25 689-699.
19. Plauth M, Merli M, Kondrup J,Weimann A, Ferenci P & Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clinical Nutrition 1997 16 43-55.
20. Harris JA & Benedict FG. A biometric study of basal metabolism in man. Publication No 270. Carnigie Institute ofWashington DC 1919.
21. Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau JM, Berger E, Blum U, Gabelmann A & Hauenstein K. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. New England Journal of Medicine 1994 330 165-171.
22. Andersen L, Dinesen B, Jorgensen PN, Poulsen F & Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clinical Chemistry 1993 39 578-582.
23. Orskov H, Thomsen HG & Yde H. Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature 1968 219 193-195.
24. Albertsson-Wikland K, Jansson C, Rosberg S & Novamo A. Time-resolved immunofluorometric assay of human growth hormone. Clinical Chemistry 1993 39 1620-1625.
25. Frystyk J, Dinesen B & Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulinlike growth factor I and II. Growth Regulation 1995 5 169-176.
26. Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De Meyts P, Larsen MB, Christiansen JS & Frystyk J. A highly sensitive and specific assay for determination of IGF1 bioactivity in human serum. American Journal of Physiology. Endocrinology and Metabolism 2003 284 E1149-E1155.
27. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW & Flyvbjerg A. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. Journal of Clinical Endocrinology and Metabolism 2003 88 132-135.
28. Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scandinavian Journal of Clinical and Laboratory Investigation 1966 18 118-125.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
30. Kushner RF & Schoeller DA. Estimation of total body water by bioelectrical impedance analysis. American Journal of Clinical Nutrition 1986 44 417-424.
31. Lautz HU, Selberg O, Korber J, Burger M & Muller MJ. Protein-calorie malnutrition in liver cirrhosis. Clinical Investigator 1992 70 478-486.
32. Pirlich M, Schutz T, Spachos T, Ertl S, Weiss ML, Lochs H & Plauth M. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 2000 32 1208-1215.
33. Kaser S, Foger B, Waldenberger P, Nachbaur K, Propst A, Jaschke W, Vogel W & Patsch JR. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis. Journal of Hepatology 2000 33 902-906.
34. Selberg O, Bottcher J, Pirlich M, Henkel E, Manns MP & Muller MJ. Clinical significance and correlates of whole body potassium status in patients with liver cirrhosis. Hepatology Research 1999 16 36-48.
35. Scharf JG & Braulke T. The role of the IGF axis in hepatocarcinogenesis. Hormone and Metabolic Research 2003 35 685-693.
36. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. PNAS 1999 96 7324-7329.
37. Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z & Baruch Y. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. Journal of Hepatology 2008 49 34-42.
38. Ketelslegers JM, Maiter D, Maes M, Underwood LE & Thissen JP. Nutritional regulation of insulin-like growth factor-I. Metabolism 1995 44 50-57.
39. Lafortune M, Martinet JP, Denys A, Patriquin H, Dauzat M, Dufresne MP, Colombato L & Pomier-Layrargues G. Short- and long-term hemodynamic effects of transjugular intrahepatic portosystemic shunts: a Doppler/ manometric correlative study. AJR. American Journal of Roentgenology 1995 164 997-1002.
40. Sanyal AJ, Freedman AM, Luketic VA, Purdum PP III, Shiffman ML, DeMeo J, Cole PE & Tisnado J. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997 112 889-898.
41. Surratt RS, Middleton WD, Darcy MD, Melson GL & Brink JA. Morphologic and hemodynamic findings at sonography before and after creation of a transjugular intrahepatic portosystemic shunt. AJR. American Journal of Roentgenology 1993 160 627-630.
42. Edgerton DS, Lautz M, Scott M, Everett CA, Stettler KM, Neal DW, Chu CA & Cherrington AD. Insulin's direct effects on the liver dominate the control of hepatic glucose production. Journal of Clinical Investigation 2006 116 521-527.
43. Stefankova J, Safka V, Fejfar T, Hulek P, Dresslerova I & Krajina A. Effect of transjugular portosystemic shunt on insulin resistance. Vnitrní lékarství 2002 48 1017-1024.
44. Jessen N, Djurhuus CB, Jorgensen JO, Jensen LS, Moller N, Lund S & Schmitz O. Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. AJR. American Journal of Roentgenology 2005 288 E194-E199.
45. Raddatz D, Rossbach C, Buchwald A, Scholz KH, Ramadori G & NolteW. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS). Experimental and Clinical Endocrinology and Diabetes 2005 113 268-274.
46. Kondrup J & Muller MJ. Energy and protein requirements of patients with chronic liver disease. Journal of Hepatology 1997 27 239-247.
47. Merli M, Riggio O, Romiti A, Ariosto F, Mango L, Pinto G, Savioli M & Capocaccia L. Basal energy production rate and substrate use in stable cirrhotic patients. Hepatology 1990 12 106-112.
48. Romiti A, Merli M, Martorano M, Parrilli G, Martino F, Riggio O, Truscelli A, Capocaccia L & Budillon G. Malabsorption and nutritional abnormalities in patients with liver cirrhosis. Italian Journal of Gastroenterology 1990 22 118-123.
49. Schneeweiss B, Graninger W, Ferenci P, Eichinger S, Grimm G, Schneider B, Laggner AN, Lenz K & Kleinberger G. Energy metabolism in patients with acute and chronic liver disease. Hepatology 1990 11 387-393.
50. Muller MJ, Bottcher J, Selberg O, Weselmann S, Boker KH, Schwarze M, von zur Muhlen A & Manns MP. Hypermetabolism in clinically stable patients with liver cirrhosis. American Journal of Clinical Nutrition 1999 69 1194-1201.